Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin vs Vildagliptin as Add-on to Metformin in T2DM
NCT02343926Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in Hemoglobin A1c at 24 weeks. Started Dec 2014; status: completed.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02343926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343926.